Effective Biomedical Public-Private Partnerships Are About Innovation, Not Lower Drug Prices

By David Beier and John Osborn

David Beier

--

Health Affairs published this article on June 15, 2022

There is fascination of late with the prospect of exercising Bayh-Dole Act “march-in rights,” primarily as a means of reducing the price of expensive drugs that have been…

--

--

David Beier

Managing Director, Bay City Capital, San Francisco, CA. Previously Chief Domestic Policy to Vice President Al Gore. Senior corporate officer DNA and Amgen